14,020 Shares in Catalent, Inc. (NYSE:CTLT) Acquired by MBB Public Markets I LLC

MBB Public Markets I LLC bought a new position in Catalent, Inc. (NYSE:CTLT) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 14,020 shares of the company’s stock, valued at approximately $788,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Catalent in the 2nd quarter worth approximately $42,000. Mather Group LLC. purchased a new stake in Catalent in the 1st quarter worth approximately $52,000. Longfellow Investment Management Co. LLC grew its stake in Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares during the period. GAMMA Investing LLC grew its stake in Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares during the period. Finally, Sound Income Strategies LLC grew its stake in Catalent by 4,466.7% in the 1st quarter. Sound Income Strategies LLC now owns 1,370 shares of the company’s stock worth $77,000 after acquiring an additional 1,340 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts have commented on CTLT shares. Barclays lifted their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. StockNews.com initiated coverage on shares of Catalent in a research note on Thursday, September 26th. They set a “sell” rating for the company. Finally, Robert W. Baird reissued a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $59.83.

Catalent Stock Performance

NYSE:CTLT opened at $60.08 on Wednesday. The company has a current ratio of 2.52, a quick ratio of 1.96 and a debt-to-equity ratio of 1.35. The firm has a market capitalization of $10.87 billion, a price-to-earnings ratio of -9.85, a PEG ratio of 2.32 and a beta of 1.15. The firm’s fifty day simple moving average is $59.74 and its 200 day simple moving average is $57.37. Catalent, Inc. has a twelve month low of $31.80 and a twelve month high of $61.20.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Thursday, August 29th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion. As a group, equities research analysts expect that Catalent, Inc. will post 0.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. The disclosure for this sale can be found here. Insiders have sold 15,403 shares of company stock worth $902,503 in the last quarter. 0.31% of the stock is owned by corporate insiders.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.